MAD2L2 and renal cell carcinoma: Our data suggest that in t(X;1)(p11;q21)-positive renal cell carcinomas a PRCCTFE3-mediated interference with RAN-dependent MAD2B activity may lead to loss of control over cell cycle progression and, hence, malignant growth.